Whole-exome sequencing to identify genetic risk variants underlying inhibitor development in severe hemophilia A patients.
2016
The development of neutralizing antibodies (inhibitors) against coagulation factor VIII (FVIII) is the most problematic and costly complication of FVIII replacement therapy that affects up to 30% of previously untreated patients with severe hemophilia A. The development of inhibitors is a
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
52
References
22
Citations
NaN
KQI